媒體:
100
建立:
2019/10/28
管理者:
管理員9 (羽亭)
  1. 知識庫
  2. ...
  3. 2019
  4. 20191207-08 2019 胸重年會，暨胸外、呼吸治療、睡眠聯合學術會議
  5. 媒體
管理者：管理員9 (羽亭)
  1. 1.
    大會全紀錄
    1. 1.1
      2019胸重聯合年會大會手冊
    2. 1.2
      會員大會
    3. 1.3
      大會花絮
    4. 1.4
      晚宴花絮
  2. 2.
    回顧特輯
    1. 2.1
      胸腔醫學發展---電子書
  3. 3.
    胸重醫學會演講
    1. 3.1
      1207_How to Make Your Patient Comfortable and Awake in ICU
    2. 3.2
      1207_MV management in ARDS with vv ECMO
    3. 3.3
      1207_胸腔重症醫師於肺移植的角色 – 林口長庚醫院之經驗
    4. 3.4
      1207_職業與環境相關的呼吸系統疾病與台灣的職業病通報制度
    5. 3.5
      1207_The role of epigenetics in human immune responses against Mycobacterium tuberculosis infection
    6. 3.6
      1208_CTEPH Management in 2019 Reflections and Prospects for Future Research
    7. 3.7
      1208_What is the role of the microbiome in chronic airways disease
    8. 3.8
      1208_Severe asthma treatment evolution
    9. 3.9
      1208_Lessons from Hokkaido COPD cohort study
    10. 3.10
      1208_As needed ICS LABA in mild asthma, pro and con
    11. 3.11
      1208_As needed ICS LABA in mild asthma pro and con
    12. 3.12
      1208_精准、转化、整合—介入呼吸病学未来展望
    13. 3.13
      1208_BRAF, MET, and Her2 mutations in lung cancer
    14. 3.14
      1208_Application of Liquid Biopsy in Lung Cancer
    15. 3.15
      1208_The immune-modulatory effects of non-immunotherapies
    16. 3.16
      1208_Air Pollution and Lung Health
    17. 3.17
      1208_Contact of tuberculosis at health care facilities in Japan
    18. 3.18
      1208_Real world experiences in the treatment of IPF
    19. 3.19
      1208_Multi-disciplinary discussion for differential diagnosis
  4. 4.
    Keynote speech
    1. 4.1
      Immune Checkpoint Inhibitors in Lung Cancer - Paving a New Avenue of Care
    2. 4.2
      Diaphragm weakness in the critically ill - Basic mechanisms and therapeutic opportunities
    3. 4.3
      Global trends and challenges in the management of asthma
  5. 5.
    Young investigator
    1. 5.1
      The relationship between AIR POLLUTION and LUNG CANCER in NON-SMOKERS in Taiwan
    2. 5.2
      Clinical outcomes and secondary EGFR T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
    3. 5.3
      Small Airway Dysfunction by Impulse Oscillometry in Symptomatic Patients with Preserved Pulmonary Function
  6. 6.
    Oral presentation
    1. 6.1
      OA01_CBCT-AF combined with EBUS-GS for biopsy of peripheral lung lesions
    2. 6.2
      OA02_Factors Associated with Osimertinib Effectiveness in Advanced Non-small Cell Lung Cancer with Acquired T790M Mutation
    3. 6.3
      OA03_嘉義縣肺癌篩檢計畫
    4. 6.4
      OA04_Combined Pleural Cryobiopsy Compared with Forceps Biopsy alone During Semirigid Pleuroscope in Subjects with Exudative Pleural Effusion
    5. 6.5
      OA06_Lung Adenocarcinoma with Neuroendocrine Differentiation - A Case Series Study
    6. 6.6
      OB02_NOTCH signaling & T cell differentiation in COPD
    7. 6.7
      OB03_Overestimation in severity of OSA of in-lab PSG comparing to home-based sleep testing by the wearable device
    8. 6.8
      OB04_Analysis the quality of asthma and COPD case manager patient education process – standardized patient approach and evaluation
    9. 6.9
      OB05_Overlapping With Chronic Obstructive Pulmonary Disease as a Phenotype of Bronchiectasis for Long-term Clinical Prediction
    10. 6.10
      OB06_間質幹細胞可藉由改善阻塞性睡眠呼吸中止症的細胞自噬不足來保護細胞免於間歇性缺氧誘發的細胞凋零和細胞毒性
    11. 6.11
      OC01_Induced pluripotent stem cells through leukemia inhibitory factor to attenuate neutrophil transendothelial migration in sepsi
    12. 6.12
      OC02_Two similar best respiratory system compliance in ARDS patients Analyzed by EIT
    13. 6.13
      OC03_Blocking Calcium Release-activated Calcium Channel Attenuates Ventilator-induced Endoplasmic Reticulum Stress and Lung Injury in Rats
    14. 6.14
      OC04_Induction of TREM-1 expression by ESAT6 protein of Mycobacterium tuberculosis-a mouse model study
    15. 6.15
      OC05_The role of M2a monocyte polarization and formyl peptide receptor (FPR)1/2/3 expressions in the progression from latent TB infection to active pulmonary TB disease
    16. 6.16
      OC06_Modified Dilution Technique to Reduce Colistin Crystallization at the End of Jet-Nebulized Aerosol Therapy
  7. 7.
    Satellite symposium
    1. 7.1
      1207_Are we doing too little too late in COPD management
    2. 7.2
      1207_Old soldiers never die, just still alive!(Old soldiers - 2nd-G EGFR-TKIs)
    3. 7.3
      1207_New approaches for chronic respiratory disease
    4. 7.4
      1207_Advancement in first-line therapeutics for EGFRm NSCLC — Navigation of current treatment options for stage IV NSCLC
    5. 7.5
      1207_Recent Advances and Unmet Needs in Cancer Immunotherapy
    6. 7.6
      1207_Recent Advances and Unmet Need of NSCLC with EGFR mutation
    7. 7.7
      1207_Uncommon mutation for lung adenocaricnoma
    8. 7.8
      1207_Optimal treatment strategy of ALK+ NSCLC
    9. 7.9
      1207_Optimizing Patients Management in Lung NETs
    10. 7.10
      1207_Lessons from the HiCARAT study - Hokkaido-based  Investigative Cohort Analysis for Refractory Asthma
    11. 7.11
      1207_From Immune pathway to clinical practice-the role of anti-IgE in disease modifying effect of Asthma (2019.12.7 finally 陳彥甫)
    12. 7.12
      1207_Treatment algorithm and emerging evidence of managing COPD
    13. 7.13
      1207_Triple therapies - opening spaces for hope in COPD patients
    14. 7.14
      1208_Treatment optimization in asthma
    15. 7.15
      1208_Optimized Treatment in Severe Asthma Real World Case Sharing
    16. 7.16
      1208_Potential Biomarkers for Immune Checkpoint Inhibitors
    17. 7.17
      1208_Clinical Application of NGS in lung cancer
    18. 7.18
      1208_How GINA recommendations solve real world problems in asthma
    19. 7.19
      1208_Current biologic treatment for severe asthma - A target approach with benralizumab
    20. 7.20
      1208_Closing remark
    21. 7.21
      1208_Challenges and Solutions in the Treatment of CRE infection in Taiwan
    22. 7.22
      1208_Current and emerging treatment options for Gram-negative infections
  8. 8.
    胸外醫學會演講
    1. 8.1
      1207_Management of Lung Nodules (GGN) 高雄長庚經驗
    2. 8.2
      1207_Management of lung nodules KMUH experience
    3. 8.3
      1207_1207_Management of pulmonary nodules中榮經驗
    4. 8.4
      1207_nature history of Persistent Sub-solid Nodules
    5. 8.5
      1207_Management of lung nodules 中國附醫
    6. 8.6
      1207_Lymphadenectomy is Unnecessary for Pure Ground Glass Opacity Pulmonary Nodules
    7. 8.7
      1207_台大醫院肺結節手術經驗分享
    8. 8.8
      1207_Management of Lung Nodules-MMH experences
    9. 8.9
      1207_Management of lung nodules on LDCT screening 胸腔內科醫師觀點
    10. 8.10
      1207_Pathology of early small lung adenocarcinoma
    11. 8.11
      1207_Small pulmonary nodules detected on CT scans - current strategy and potential contribution of AI
    12. 8.12
      1207_One Stop One Shop Strategy for Lung Nodules-What the Future may hold
    13. 8.13
      1207_Percutaneous Localization of Small Lung Nodules 彰基經驗
    14. 8.14
      1207_Percutaneous Localization of Small Lung Nodules 北榮經驗
    15. 8.15
      1207_Percutaneous localization of small lung nodules - 新光吳火獅紀念醫院的經驗分享
    16. 8.16
      1207_Percutaneous Localization of Small Lung Nodules - NTUH experience
    17. 8.17
      1207_Computed Tomography-guided Localization of Pulmonary Nodules in VATS
    18. 8.18
      1207_Percutaneous Localization of Small Lung Nodules 奇美經驗
    19. 8.19
      1207_Management of bronchopleural fistula in a patient receiving pneumonectomy for recurrent lung cancer
    20. 8.20
      1207_胸腔外科困難個案討論會 - Early thrombotic microangiopathy following lung transplantation
    21. 8.21
      1207_Tumor localization - Navigation Bronchoscopy Approach
    22. 8.22
      1207_Endobronchial Localization of Small Lung Nodules - MacKay Memorial Hospital Epx
    23. 8.23
      1207_Real-time Image-guided Electromagnetic Navigational Bronchoscopy Dual-marker Technique to Localize Deep Pulmonary N
    24. 8.24
      1207_胸腔外科困難個案討論會 Mediastinal growing teratoma syndrome
    25. 8.25
      1207_Post-CCRT esophageal perforation - a devastating condition
  9. 9.
    呼吸治療學會演講
    1. 9.1
      1207_Update in aerosolized drug delivery through mechanical ventilation
    2. 9.2
      1207_Molecular Mechanisms of Ventilator-Induced Lung Injury
    3. 9.3
      1207_Melatonin in the treatment of metastatic lung cancer - preclinical and molecular mechanism study
  10. 10.
    睡眠醫學學會演講
    1. 10.1
      1208_CPAP and NIV in Japan
    2. 10.2
      1208_The biomarker of endothelial damage in obstructive sleep apnea
    3. 10.3
      1208_Non-Invasive Ventilation in the Treatment of Sleep-Disordered Breathing
    4. 10.4
      1208_Sleep disturbance and circadian disruption in critically ill patients
社團法人台灣胸腔暨重症加護醫學會 (統一編號00955461)
會　　址：108台北市萬華區中華路一段74號4樓
胸 重 醫 學 會 秘書處　電話：02-2314-4089 ｜ 傳真：02-2314-1289 ｜ Email：tspccm.t6237@msa.hinet.net
胸腔醫學雜誌 編輯部　電話：02-2314-4086 ｜ Email：chest_medicine@yahoo.com.tw
TEL：+886-2-2314-4089   │
Address：4F., No. 74, Sec. 1, Zhonghua Rd., Wanhua Dist., Taipei City 108002, Taiwan
著作權政策：所有資料皆受著作權保護，未經授權不得使用。影音檔及投影片等之著作權仍屬於原講者，未經原講者同意不得引用或轉載。